Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of intramuscular teverelix loading-dose regimen in advanced prostate cancer
2004-001648-64Phase 2Completed
- Sponsor
- Ardana
- Start
- Sep 2004
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of teverelix in prostate cancer (PCa), sponsored by Ardana. Primary endpoint: Duration of testosterone suppression below castrate level. Started Sep 2004; status: completed.
02
Drugs
teverelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2004-001648-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001648-64.